SCHEDULE: Atlas Venture Reduces Sionna Therapeutics Stake

Atlas Venture entities have reduced their collective beneficial ownership in Sionna Therapeutics, Inc. to 7.0% through recent share sales.

Summary

• Atlas Venture entities filed an Amendment No. 1 to their Schedule 13D regarding their stake in SIONNA THERAPEUTICS, INC.
• Atlas Venture Fund XI, L.P. and its related entities beneficially own 2,382,495 shares, representing 5.4% of the Issuer's Common Stock.
• Atlas Venture Opportunity Fund II, L.P. and its related entities beneficially own 701,985 shares, representing 1.6% of the Issuer's Common Stock.
• Collectively, the Reporting Persons beneficially own 3,084,480 shares, which constitutes 7.0% of SIONNA THERAPEUTICS, INC.'s outstanding Common Stock.
• This percentage is based on 44,139,823 outstanding shares as reported in the Issuer's Form 10-Q on August 11, 2025.
• Numerous sales transactions by Atlas XI and AVOF II occurred between September 29, 2025, and October 20, 2025, with prices ranging from $29.95 to $33.86 per share.
• The Reporting Persons disclaim being a 'group' for Section 13 purposes, despite being under common control.

Sentiment

Score: 4

Explanation: The filing indicates a significant institutional investor, Atlas Venture, has been actively selling shares and reducing its stake in Sionna Therapeutics. While this could be part of a normal portfolio management strategy, it generally signals a less positive outlook or a decision to exit a position, which can be perceived negatively by the market.

Negatives

• Significant sales of common stock by Atlas Venture entities indicate a reduction in their investment in SIONNA THERAPEUTICS, INC.
• The collective beneficial ownership of Atlas Venture entities has decreased to 7.0% of the outstanding common stock.

Risks

• The reduction in stake by a significant institutional investor like Atlas Venture could be perceived as a negative signal regarding the company's future prospects or valuation.

Future Outlook

NA

Management Comments

• I certify that the information set forth in this statement is true, complete and correct.

Industry Context

This filing reflects a venture capital firm's decision to reduce its stake in a publicly traded company. Such actions are common in the lifecycle of venture investments, where firms may divest holdings after a certain period or based on portfolio rebalancing strategies. Without further context on Sionna Therapeutics' specific industry, it generally indicates a shift in investor confidence or strategy for the specific holding.

Stakeholder Impact

• Shareholders: The reduction in stake by a major institutional investor could lead to negative market sentiment and potentially impact share price.
• Company Management: May face questions regarding the reasons for the significant investor's divestment.

Key Dates

Recommendation

The consistent and significant selling activity by Atlas Venture, a prominent institutional investor, suggests a diminishing conviction in Sionna Therapeutics' future prospects or valuation. While the specific reasons for their divestment are not detailed, such a reduction in a major stake often precedes or accompanies negative developments, or at minimum, indicates that the investor believes the stock has reached its peak or that better opportunities exist elsewhere. This action could exert downward pressure on the stock price and signals a cautious stance for other investors.

Keywords

Sionna Therapeutics, Atlas Venture, Schedule 13D/A, beneficial ownership, common stock, share sales, SEC filing